Skip to main content
OpenTrials
Completed

NCT Number: NCT02568722

Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)

The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared to standard initiation, leads to:

1. Improved survival (primary outcome); and 2. Recovery of kidney function (principal secondary outcome), defined as independence from RRT at 90 days

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ballarat Hospital, Ballarat, Australia

Loading trial locations.

About this study

Acute kidney injury (AKI) is a common and devastating complication of critical illness. Once AKI is established, treatment is largely supportive and no intervention has been found to restore kidney function or improve overall survival. Renal replacement therapy (RRT), usually in the form of hemodialysis, is frequently needed to manage patients with severe AKI. Such patients have an in-hospital mortality that consistently exceeds 50% with delays in RRT initiation implicated as a possible contributor. A recent meta-analysis suggested that earlier initiation of RRT may improve survival, but this is based on data derived overwhelmingly from observational studies. The investigators recently completed a multi-centre randomized controlled pilot trial that confirmed the feasibility of allocating patients to two different strategies of RRT initiation. Patient recruitment and follow-up, as well as patient safety, were successfully demonstrated during the pilot phase of this research program. The optimal timing of RRT initiation is an existing knowledge gap and a clear priority for investigation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Admission to an intensive care unit (ICU)
  • Evidence of kidney dysfunction [serum creatinine ≥100 µmol/L (women) and ≥ 130 µmol/L (men)]
  • Evidence of severe AKI defined by at least 1 of the following 3 criteria:

i) ≥ 2-fold increase in serum creatinine from a known pre-morbid baseline or during the current hospitalization; OR ii) Achievement of a serum creatinine ≥ 354 µmol/L with evidence of a minimum increase of 27 µmol/L from pre-morbid baseline or during the current hospitalization; OR iii) Urine output < 6.0 mL/kg over the preceding 12 hours

Exclusion criteria

  • Serum potassium > 5.5 mmol/L
  • Serum bicarbonate < 15 mmol/L
  • Presence of a drug overdose that necessitates initiation of RRT
  • Lack of commitment to ongoing life support (including RRT)
  • Any RRT within the previous 2 months (either acute or chronic RRT)
  • Kidney transplant within the past 365 days
  • Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate < 20 mL/min/1.73 m2
  • Presence or clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis
  • Clinician(s) caring for patient believe(s) that immediate RRT is mandated
  • Clinician(s) caring for patient believe(s) that deferral of RRT initiation is mandated
  • at their discretion, clinicians may administer a bolus of intravenous furosemide (ie, "furosemide stress test") and evaluate the subsequent urine output to help guide decision making regarding the likelihood of AKI progression

Treatment and study plan

Standard RRT initiation

Other

In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:

serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization.

Accelerated RRT initiation

Other

A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.

Primary outcomes

  1. All-cause Mortality.

    Time frame: 90 days following study randomization.

Secondary outcomes

  1. RRT Dependence

    Time frame: 90 days following study randomization.

  2. Composite of Death or RRT Dependence.

    Time frame: 90 days following study randomization.

  3. Measurement of Estimated Glomerular Filtration Rate.

    Time frame: 90 days following study randomization.

  4. Measurement of Albuminuria.

    Time frame: 90 days following study randomization.

  5. Major Adverse Kidney Outcomes.

    Time frame: 90 days following study randomization.

    Defined as death, RRT dependence or sustained reduction in kidney function (defined as eGFR < 75% baseline eGFR).

  6. Mechanical Ventilation-free Days.

    Time frame: Measured from randomization through day 28.

  7. Vasoactive Therapy-free Days

    Time frame: Measured from randomization through day 28.

  8. ICU-free Days

    Time frame: Measured from randomization through day 28.

  9. Hospitalization-free Days

    Time frame: Measured from randomization through day 90.

  10. Death in ICU

    Time frame: Measured in-hospital and at day 28.

  11. EuroQoL EQ-5D-5L.

    Time frame: Measured at day 90 and at day 365.

    A measure of health-related quality of life and patient utility.

  12. Health Care Costs.

    Time frame: Measured from baseline through day 365.

  13. Composite of Death or RRT Dependence.

    Time frame: Measured at day 365.

Sponsors and collaborators

Lead sponsor

Unity Health Toronto

Other

Collaborators

  • Baxter Healthcare Corporation
  • Canadian Institutes of Health Research (CIHR)
  • Health Research Council, New Zealand
  • Medical Research Institute of New Zealand
  • National Health and Medical Research Council, Australia
  • National Institute for Health Research, United Kingdom
  • The George Institute

Registry information

Official study title

STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial (Principal Trial)

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Oct 6, 2015
Registry last updated
Oct 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.